OS Therapies Terminates Material Agreement

TL;DR

OS Therapies terminated a key deal, filing an 8-K on Aug 25, 2025.

AI Summary

On August 25, 2025, OS Therapies Inc. filed an 8-K report indicating the termination of a material definitive agreement. The filing also noted other events and the submission of financial statements and exhibits. The company, incorporated in Delaware, is based in Grasonville, Maryland.

Why It Matters

The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.

Risk Assessment

Risk Level: medium — Termination of a material definitive agreement often signals significant business challenges or strategic shifts that could affect the company's performance.

Key Players & Entities

• OS Therapies Inc. (company) — Registrant
• August 25, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Grasonville, Maryland (location) — Address of Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share OSTX NYSE American Indi
• $15.0 million — the right to sell to Square Gate up to $15.0 million of its shares of common stock, subject

Filing Documents

• ea0254579-8k_ostherap.htm (8-K) — 28KB
• ea025457901ex99-1_ostherap.htm (EX-99.1) — 9KB
• 0001213900-25-080484.txt ( ) — 204KB
• ostx-20250825.xsd (EX-101.SCH) — 3KB
• ostx-20250825_lab.xml (EX-101.LAB) — 33KB
• ostx-20250825_pre.xml (EX-101.PRE) — 22KB
• ea0254579-8k_ostherap_htm.xml (XML) — 4KB

02. Termination of a Material Definitive

Item 1.02. Termination of a Material Definitive Agreement. On August 25, 2025, OS Therapies Incorporated (the "Company") delivered to Square Gate Capital Master Fund, LLC — Series 3 ("Square Gate") a notice to terminate the Equity Purchase Agreement, dated as of October 31, 2024 (the "ELOC Purchase Agreement"), pursuant to Section 10.6 thereof. The termination became effective on August 26, 2025. As previously disclosed, the ELOC Purchase Agreement provided the Company with the right to sell to Square Gate up to $15.0 million of its shares of common stock, terminate, and at the time of termination, there were no outstanding borrowings, advance notices or shares of common stock to be issued under the ELOC Purchase Agreement. In addition, no termination fees or other payments were due by either party in connection with the termination of the ELOC Purchase Agreement.

01. Other Events

Item 8.01. Other Events. On August 25, 2025, the Company issued a press release announcing the termination of the ELOC Purchase Agreement.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by OS Therapies Incorporated on August 25, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OS THERAPIES INCORPORATED Dated: August 26, 2025 By: /s/ Paul A. Romness, MPH Name: Paul A. Romness, MPH Title: President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR